Compare MRT & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRT | CNTN |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | Turkey | United States |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.4M | 178.5M |
| IPO Year | 2021 | 2021 |
| Metric | MRT | CNTN |
|---|---|---|
| Price | $1.78 | $2.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $5.04 | N/A |
| AVG Volume (30 Days) | 43.5K | ★ 835.5K |
| Earning Date | 08-08-2018 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.10 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $116.52 | N/A |
| Revenue Next Year | $59.73 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.12 | $1.75 |
| 52 Week High | $2.75 | $5.27 |
| Indicator | MRT | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 38.11 | 41.64 |
| Support Level | $1.63 | $2.04 |
| Resistance Level | $1.87 | $2.40 |
| Average True Range (ATR) | 0.11 | 0.16 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 5.66 | 5.06 |
Marti Technologies Inc is Turkiye's urban mobility platform, helping to solve the country's transportation needs through tech-enabled services powered by a single mobility super app. The Group aims to offer tech-enabled urban transportation services to consumers across Turkiye through three service offerings: ride-hailing, delivery, and two-wheeled electric vehicle services. The Group's ride-hailing service matches consumers with car, motorcycle, and taxi drivers. The Group's delivery service provides same-hour package delivery by leveraging the Group's existing network of car and motorcycle drivers and consumer base.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.